Purdue Sues TWi Over Insomnia Drug Generic Plans
According to Purdue, Taiwanese drugmaker TWi’s planned 1.75- and 3.5-milligram dose sublingual tablet versions of zolpidem tartrate infringe on two patents — U.S. Patent Numbers 8,242,131 and 8,252,809 — covering Intermezzo, exclusively licensed to Purdue by drug development company Transcept Pharmaceuticals Inc.
“Plaintiffs will be irreparably harmed if TWi is not...
Already a subscriber? Click here to login